Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March–April 2021
Author(s) -
Heidi L Moline,
Amelia A. Keaton,
Whitney Rice,
Jasmine Varghese,
Li Deng,
Ansley Waters,
Anna Barringer,
Devonne Winston,
Virgie Fields,
Kara Jacobs Slifka,
Jennifer R. Verani,
Stephanie J. Schrag,
John A. Jernigan,
Jacqueline E. Tate,
Katherine E. Fleming-Dutra
Publication year - 2022
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciac526
Subject(s) - medicine , outbreak , context (archaeology) , covid-19 , coronavirus , vaccination , virology , betacoronavirus , disease , immunology , infectious disease (medical specialty) , biology , paleontology
In April 2021, we assessed mRNA vaccine effectiveness (VE) in the context of a COVID-19 outbreak in a skilled nursing facility. Among 28 cases, genomic sequencing was performed on 4 specimens on 4 different patients, and all were classified by sequence analysis as the Beta (B.1.351) variant. Adjusted VE among residents was 65% (95% confidence interval: 25-84%). These findings underscore the importance of vaccination for prevention of COVID-19 in skilled nursing facilities.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom